Clinical trial
9-ING-41 in Patients With Advanced Cancers
NCT03678883
Study timeline
Study start (actual)2019-01-04Date precision: day
Registry last updated2026-04-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Cancerunresolved
Pancreatic Cancerunresolved
Sarcomaunresolved
Renal Cancerunresolved
Refractory Cancerunresolved
Refractory Neoplasmunresolved
Refractory Non-Hodgkin Lymphomaunresolved
Pancreatic Adenocarcinomaunresolved
Resistant Cancerunresolved
Neoplasm Metastasisunresolved
Neoplasm of Boneunresolved
Neoplasm, Breastunresolved
Neoplasm of Lungunresolved
Neoplasms,Colorectalunresolved
Neoplasms Pancreaticunresolved
Malignant Gliomaunresolved
Malignanciesunresolved
Malignancies Multipleunresolved
Bone Metastasesunresolved
Bone Neoplasmunresolved
Bone Cancerunresolved
Pancreas Cancerunresolved
Pancreatic Neoplasmsunresolved
Breast Neoplasmsunresolved
Acute T Cell Leukemia Lymphomaunresolved
Interventions
9-ING-41DRUG
Doxorubicin.DRUG
LomustineDRUG · verified · RxNorm: lomustine
Carboplatin.DRUG
Nab paclitaxel.DRUG
Paclitaxel.DRUG
IrinotecanDRUG · verified · RxNorm: irinotecan
Sponsors & collaborators
Actuate Therapeutics Inc.lead sponsor
Mapped research locations
DallasTexas, United States2NashvilleTennessee, United States2MadridSpain2BarcelonaSpain2MontrealQuebec, Canada2TucsonArizona, United States2LisbonPortugal2New YorkNew York, United States1ChicagoIllinois, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03678883 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.